EP0879279A4 - Diabetestherapie - Google Patents

Diabetestherapie

Info

Publication number
EP0879279A4
EP0879279A4 EP97905834A EP97905834A EP0879279A4 EP 0879279 A4 EP0879279 A4 EP 0879279A4 EP 97905834 A EP97905834 A EP 97905834A EP 97905834 A EP97905834 A EP 97905834A EP 0879279 A4 EP0879279 A4 EP 0879279A4
Authority
EP
European Patent Office
Prior art keywords
diabetes therapy
diabetes
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97905834A
Other languages
English (en)
French (fr)
Other versions
EP0879279A1 (de
Inventor
Tracy L Borts
Carol L Broderick
Richard D Dimarchi
Brian W Grinnell
Anne R Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9603847.6A external-priority patent/GB9603847D0/en
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of EP0879279A1 publication Critical patent/EP0879279A1/de
Publication of EP0879279A4 publication Critical patent/EP0879279A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
EP97905834A 1996-02-06 1997-02-06 Diabetestherapie Withdrawn EP0879279A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1211196P 1996-02-06 1996-02-06
US12111P 1996-02-06
GB9603847 1996-02-23
GBGB9603847.6A GB9603847D0 (en) 1996-02-23 1996-02-23 Diabetes therapy
PCT/US1997/001978 WO1997029180A1 (en) 1996-02-06 1997-02-06 Diabetes therapy

Publications (2)

Publication Number Publication Date
EP0879279A1 EP0879279A1 (de) 1998-11-25
EP0879279A4 true EP0879279A4 (de) 2000-07-12

Family

ID=26308793

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97905834A Withdrawn EP0879279A4 (de) 1996-02-06 1997-02-06 Diabetestherapie

Country Status (5)

Country Link
EP (1) EP0879279A4 (de)
JP (1) JP2001503963A (de)
AU (1) AU2263197A (de)
CA (1) CA2243718A1 (de)
WO (1) WO1997029180A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117641A (en) 1996-04-11 2000-09-12 Mitotix, Inc. Assays and reagents for identifying anti-fungal agents and uses related thereto
US6727082B1 (en) 1996-04-11 2004-04-27 Gpc Biotech Inc. Assays and reagents for identifying anti-fungal agents, and uses related thereto
CA2251593A1 (en) 1996-04-11 1997-10-16 Mitotix, Inc. Assays and reagents for identifying anti-fungal agents, and uses related thereto
US5981488A (en) * 1997-03-31 1999-11-09 Eli Lillly And Company Glucagon-like peptide-1 analogs
AU6586298A (en) * 1997-03-31 1998-10-22 Eli Lilly And Company Glucagon-like peptide-1 analogs
AU3047299A (en) * 1998-04-13 1999-11-01 Modex Therapeutiques, S.A. Methods of delivering glp-1
JP3702181B2 (ja) 1998-12-07 2005-10-05 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス Ｇｌｐ−１の類似体
ATE394423T1 (de) * 1998-12-07 2008-05-15 Sod Conseils Rech Applic Analoge des glucagon ähnlichen peptides-1 (glp-1)
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
WO2000062862A1 (en) * 1999-04-15 2000-10-26 South Eastern Sydney Area Health Service Method of prophylaxis and treatment of diabetes
WO2001035988A1 (en) * 1999-11-12 2001-05-25 Novo Nordisk A/S Use of glp-1 agonists for the inhibition of beta cell degeneration
US6569832B1 (en) 1999-11-12 2003-05-27 Novo Nordisk A/S Inhibition of beta cell degeneration
US7229793B1 (en) 1999-11-19 2007-06-12 Shire Human Genetic Therapies, Inc. Constructs and cells for production of small peptides
US20020025306A1 (en) * 2000-01-07 2002-02-28 Baetge Edward E. Methods of increasing the glucose responsiveness of pancreatic ss-cells
CN1363654A (zh) * 2001-07-19 2002-08-14 上海华谊生物技术有限公司 生产促胰岛素分泌肽glp－1(7－36)的基因工程菌以及生产glp－1(7－36)的方法
JP2007514752A (ja) 2003-12-16 2007-06-07 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス Ｇｌｐ−１医薬組成物
EP2210900A3 (de) 2003-12-16 2010-08-11 Ipsen Pharma GlLP-1-Analoga
TW200643033A (en) * 2005-03-08 2006-12-16 Chugai Pharmaceutical Co Ltd Conjugate of water-soluble modified hyaluronic acid and glp-1 analogue
ES2507098T3 (es) 2005-11-07 2014-10-14 Indiana University Research And Technology Corporation Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas
RU2477286C2 (ru) 2007-01-05 2013-03-10 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн АНАЛОГИ ГЛЮКАГОНА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ РАСТВОРИМОСТЬЮ В БУФЕРАХ С ФИЗИОЛОГИЧЕСКИМ ЗНАЧЕНИЕМ pH
EP2487184A1 (de) 2007-02-15 2012-08-15 Indiana University Research and Technology Corporation Coagonisten des Glucagon/GLP-1-Rezeptors
CA2702289A1 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
AU2008318986B2 (en) 2007-10-30 2014-12-04 Indiana University Research And Technology Corporation Glucagon antagonists
TR201100184T1 (tr) 2008-04-09 2011-04-21 Cornell University Memeli Bir Konakçı İçerisinde Sinyal Mediyatörü Olarak Ortakçı Bakteriler
EP2300037B1 (de) 2008-06-17 2016-03-30 Indiana University Research and Technology Corporation Coagonisten des glucagon/glp-1 rezeptors
CN104447980A (zh) 2008-06-17 2015-03-25 印第安纳大学研究及科技有限公司 在生理pH缓冲液中具有增强的溶解性和稳定性的胰高血糖素类似物
PE20100056A1 (es) 2008-06-17 2010-01-26 Univ Indiana Res & Tech Corp Analogos de glucagon como agonistas gip
CN102325539A (zh) 2008-12-19 2012-01-18 印第安纳大学研究及科技有限公司 基于酰胺的胰高血糖素超家族肽前药
MX2011013625A (es) 2009-06-16 2012-01-20 Univ Indiana Res & Tech Corp Compuestos glucagon activo de receptor de gip.
WO2011075393A2 (en) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
JP2013518115A (ja) 2010-01-27 2013-05-20 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション 代謝疾患及び肥満の治療のためのグルカゴンアンタゴニスト‐ｇｉｐアゴニスト複合体及び組成物
BR112012028704A2 (pt) 2010-05-13 2019-09-24 Univ Indiana Res & Tech Corp composto de glugagon da superfamília de peptídeos exibindo atividade do receptor com hormônio nuclear, pró fármaco, dímero ou multímero, composição farmacêutica que o compreendem e método de administração do mesmo.
CA2797089A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
KR20130102470A (ko) 2010-06-24 2013-09-17 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 아미드계 글루카곤 슈퍼패밀리 펩티드 프로드러그
WO2012051431A2 (en) 2010-10-15 2012-04-19 Cornell University Compositions and methods for treating endocrine, gastrointestinal or autoimmune disorders
CN103458920B (zh) 2010-12-22 2016-07-06 印第安那大学科技研究公司 表现出gip受体活性的胰高血糖素类似物
KR20140043793A (ko) 2011-06-22 2014-04-10 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/glp-1 수용체 공동-작용물질
RS56173B1 (sr) 2011-06-22 2017-11-30 Univ Indiana Res & Tech Corp Koagonisti receptora za glukagon/glp-1 receptora
RU2014117678A (ru) 2011-11-17 2015-12-27 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Пептиды глюкагонового суперсемейства, обладающие глюкокортикоидной рецепторной активностью
KR20150023013A (ko) 2012-06-21 2015-03-04 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 수용체 활성을 나타내는 글루카곤 유사체
CA3177693A1 (en) 2019-04-05 2020-10-05 Eli Lilly And Company Therapeutic uses of dulaglutide

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0499990A2 (de) * 1991-02-19 1992-08-26 Takeda Chemical Industries, Ltd. Verfahren zur Herstellung von cysteinfreien Peptiden
WO1993009222A2 (en) * 1991-11-05 1993-05-13 Transkaryotic Therapies, Inc. Transfection of vertebrate cells e.g. by homologous recombination
EP0619322A2 (de) * 1993-04-07 1994-10-12 Pfizer Inc. Verzögerte Freigabe von Peptiden
WO1995003405A2 (en) * 1993-07-20 1995-02-02 Bionebraska, Inc. Enzymatic method for modification of recombinant polypeptides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
GB9502830D0 (en) * 1995-02-14 1995-04-05 Ecole Polytech Regulation of polypeptide production in cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0499990A2 (de) * 1991-02-19 1992-08-26 Takeda Chemical Industries, Ltd. Verfahren zur Herstellung von cysteinfreien Peptiden
WO1993009222A2 (en) * 1991-11-05 1993-05-13 Transkaryotic Therapies, Inc. Transfection of vertebrate cells e.g. by homologous recombination
EP0619322A2 (de) * 1993-04-07 1994-10-12 Pfizer Inc. Verzögerte Freigabe von Peptiden
WO1995003405A2 (en) * 1993-07-20 1995-02-02 Bionebraska, Inc. Enzymatic method for modification of recombinant polypeptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9729180A1 *

Also Published As

Publication number Publication date
AU2263197A (en) 1997-08-28
EP0879279A1 (de) 1998-11-25
WO1997029180A1 (en) 1997-08-14
CA2243718A1 (en) 1997-08-14
JP2001503963A (ja) 2001-03-27

Similar Documents

Publication Publication Date Title
EP0879279A4 (de) Diabetestherapie
EG24678A (en) Combination therapy
PL331901A1 (en) Syringe
PL331209A1 (en) Syringe
AP2002002661A0 (en) Combination therapy for oesteoporosis
ZA982368B (en) New therapeutic combinations
IL127306A0 (en) Combination therapy
ZA9533B (en) Pentolifylline therapy
GB9700899D0 (en) Novel treatment
ZA973209B (en) Therapeutic compounds.
GB9700939D0 (en) Therapy
GB9600143D0 (en) Therapeutic compounds
GB9606076D0 (en) Diabetes treatment
GB9620777D0 (en) Therapeutic use
GB9901108D0 (en) Anti-reuse syringe
HUP0000089A3 (en) Syringe
ZA9711533B (en) Therapeutic compounds
ZA977005B (en) Therapeutic uses
GB9603847D0 (en) Diabetes therapy
GB2304046B (en) Diabetes therapy
GB9617550D0 (en) Medical ice-pack
GB9721692D0 (en) Novel treatment
GB9605525D0 (en) Therapy
GB9605466D0 (en) Therapy
GB9410971D0 (en) Diabetes treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980727

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: RO PAYMENT 980727

A4 Supplementary search report drawn up and despatched

Effective date: 20000526

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 20020913

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030124

R18D Application deemed to be withdrawn (corrected)

Effective date: 20030325